CytomX Therapeutics
CTMXCytomX Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of conditionally activated biologics for oncology.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
CytomX Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of conditionally activated biologics for oncology. The company utilizes its proprietary PROBODY technology platform to design masked antibodies that are activated by proteases specifically within the tumor microenvironment. This approach aims to minimize systemic toxicity and expand the therapeutic index for potent drug modalities such as antibody-drug conjugates and T-cell engagers.
A pioneer in the field of conditionally activated biologics with over 15 years of experience in protease-inhibited masking technology.
Questions, answered.
- What is CytomX Therapeutics's market cap?
- CytomX Therapeutics (CTMX) has a market capitalization of $707.5M and trades on NASDAQ.
- What is CytomX Therapeutics's revenue and profitability?
- CytomX Therapeutics generated $35.5M in trailing twelve-month revenue with a net loss of $59.1M, representing a net margin of -166.4%, with free cash flow of -$80.2M. These figures are based on the Q1 2026 filing.
- Who are CytomX Therapeutics's competitors?
- CytomX Therapeutics's key competitors include Seagen, Amgen, Immunome, Inc., and others. These companies compete in similar markets and product categories.
- Who does CytomX Therapeutics partner with?
- CytomX Therapeutics's notable partners include AbbVie, Bristol-Myers Squibb, Amgen.
- Where is CytomX Therapeutics headquartered?
- CytomX Therapeutics is headquartered in United States of America and employs approximately 122 people. It has been publicly traded since 2015.
